Related Experiment Video
Updated: Jun 7, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
The Fluid-phase SC5b-9 Terminal Complement Complex Binds to the GPIIb/IIIa Complex of Thrombin-stimulated Human Blood
We have investigated interactions between human blood platelets and the vitronectin-containing fluid-phase terminal complement complex, the SC5b-9, which is a non-cytolytic variant of the membrane attack complex C%9(m). SC5b-9 affinity for the platelet membrane glycoprotein IIb/IIIa (GPIIb/IIIa) complex was demonstrated by crossed radio-immunoelectrophoresis of solubilized, washed platelets followed by incubation of the immunoplates with (125)I-labelled SC5b-9 and exposure to X-ray films. Platelet adhesion to surfaces of polystyrene coated with the SC5b-9 complex was studied under static conditions in an enzyme immunoassay (EIA). Thrombin-stimulated platelets but not non-stimulated platelets adhered to the SCSb-9coated surface, and platelet adherence was inhibited in a dose-dependent manner by the tetrapeptide RGDS (Arg-Gly-Asp-Ser). This indicates an interaction between platelet GPIIb/IIIa and an RGD sequence in SC5b-9, possibly in its vitronectin moiety. The effect of the SC5b-9 complex on platelet aggregation was examined in a dual-channel aggregometer. Here the SC5b-9 complex inhibited both ADP-and thrombin-induced platelet aggregation in a dose-dependent manner. These results were confirmed by electron microscopical examination of the contents of the aggregometer cuvettes. Platelets which had been thrombin-stimulated in the presence of SC5b-9 appeared activated and had undergone secretion, but showed no aggregation. By contrast, platelets from the control experiments which had been thrombin-stimulated in the absence of SC5b-9 were aggregated. To the best of our knowledge, this is the 6rst report on a biological role of the SC5b-9 complex in platelet function.
We have investigated interactions between human blood platelets and the vitronectin-containing fluid-phase terminal complement complex, the SC5b-9, which is a non-cytolytic variant of the membrane attack complex C%9(m). SC5b-9 affinity for the platelet membrane glycoprotein IIb/IIIa (GPIIb/IIIa) complex was demonstrated by crossed radio-immunoelectrophoresis of solubilized, washed platelets followed by incubation of the immunoplates with (125)I-labelled SC5b-9 and exposure to X-ray films. Platelet adhesion to surfaces of polystyrene coated with the SC5b-9 complex was studied under static conditions in an enzyme immunoassay (EIA). Thrombin-stimulated platelets but not non-stimulated platelets adhered to the SCSb-9coated surface, and platelet adherence was inhibited in a dose-dependent manner by the tetrapeptide RGDS (Arg-Gly-Asp-Ser). This indicates an interaction between platelet GPIIb/IIIa and an RGD sequence in SC5b-9, possibly in its vitronectin moiety. The effect of the SC5b-9 complex on platelet aggregation was examined in a dual-channel aggregometer. Here the SC5b-9 complex inhibited both ADP-and thrombin-induced platelet aggregation in a dose-dependent manner. These results were confirmed by electron microscopical examination of the contents of the aggregometer cuvettes. Platelets which had been thrombin-stimulated in the presence of SC5b-9 appeared activated and had undergone secretion, but showed no aggregation. By contrast, platelets from the control experiments which had been thrombin-stimulated in the absence of SC5b-9 were aggregated. To the best of our knowledge, this is the 6rst report on a biological role of the SC5b-9 complex in platelet function.
Related Concept Videos
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Complement System
Clot Retraction and Fibrinolysis
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

